Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (11)
Type
Type
Guidance (309)
Quality standard (29)
Guidance programme
Guidance programme
Health technology evaluations (8)
Highly specialised technologies guidance (1)
Interventional procedures guidance (10)
Medical technologies guidance (4)
Technology appraisal guidance (288)
Apply filters
Showing 271 to 280 of 338
Guidance and quality standards awaiting development
Title
Type
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs
Quality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]
Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]
Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]
Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Technology appraisal guidance
Staged bilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
Interventional procedures guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Technology appraisal guidance
STS101 for treating acute migraine [TSID11782]
Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]
Technology appraisal guidance
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081
Technology appraisal guidance
Previous page
1
…
26
27
Current page
28
29
30
…
34
Page
28
of
34
Next page
Results per page
10
25
50
All
Back to top